We’re Hiring! View Open Positions

Archives

Last 20 Posts

 
  1. Enzyvant Receives FDA Approval for RETHYMIC® (allogeneic processed thymus tissue-agdc), a One-Time Regenerative Tissue-Based Therapy for Pediatric Congenital Athymia
  2. Sumitomo Pharma Subsidiary Companies in the U.S., Including Sumitovant and its Wholly Owned Subsidiaries, to Combine and Form Sumitomo Pharma America
  3. Enzyvant Announces Merger with Altavant
  4. 43rd Annual Meeting & Scientific Sessions of the ISHLT
  5. Alliance for Regenerative Medicine (ARM) Cell & Gene Meeting on the Mediterranean
  6. ACC.23 Together With WCC
  7. PCMA Business Forum 2023
  8. American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting 2023
  9. 45th Annual Pulmonary and Allergy Update
  10. American Thoracic Society (ATS) 2022
  11. Altavant Sciences Presents Data Showing Potential for Combination of Rodatristat Ethyl and Ambrisentan in Model of Pulmonary Arterial Hypertension
  12. Altavant Sciences Presented Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530
  13. International Society for Heart & Lung Transplantation (ISHLT)
  14. Altavant Sciences to Present Data at ISHLT Showing Potency and Distribution of Bronchiolitis Obliterans Candidate, ALTA-2530
  15. Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
  16. SCOPE Europe 2022
  17. Sumitovant and Enzyvant Appoint Bill Symonds, CEO of Altavant Sciences, as Interim Chief Executive Officer of Enzyvant
  18. Enzyvant Appoints Johanna Rossell as Chief Commercial Officer
  19. Altavant Sciences Highlights Ongoing Phase 2b ELEVATE 2 Study of Rodatristat Ethyl in Patients with Pulmonary Arterial Hypertension at European Respiratory Society Annual Congress
  20. European Respiratory Society International Congress 2021

By Month

 

Contact us for more information

Contact Us